Novel Tetrahydroquinazolinamines as Selective Histamine 3 Receptor Antagonists for the Treatment of Obesity
作者:Ajeet Kumar、Venkata Reddy Pasam、Ravi Kumar Thakur、Maninder Singh、Kartikey Singh、Mahendra Shukla、Anubhav Yadav、Shalini Dogra、Chandan Sona、Deepmala Umrao、Swati Jaiswal、Hafsa Ahmad、Mamunur Rashid、Sandeep K. Singh、Muhammad Wahajuddin、Anil Kumar Dwivedi、Mohammad Imran Siddiqi、Jawahar Lal、Rama Pati Tripathi、Prem N. Yadav
DOI:10.1021/acs.jmedchem.9b00241
日期:2019.5.9
as selective H3R antagonists. Among all the synthesized compounds, in vitro and docking studies suggested that the 4-methoxy-phenyl-substituted tetrahydroquinazolinamine compound 4c has potent and selective H3R antagonist activity (IC50 < 0.04 μM). Compound 4c did not exhibit any activity on the hERG ion channel and pan-assay interference compounds liability. Pharmacokinetic studies showed that 4c crosses
组胺3受体(H3R)是一种突触前受体,可调节多种神经递质,包括组胺和各种基本生理过程,如进食,唤醒,认知和疼痛。H3R被认为是治疗几种中枢神经系统疾病的药物靶标。我们已经合成和鉴定了一系列新型的4-芳基-6-甲基-5,6,7,8-四氢喹唑啉胺,它们可以作为选择性的H3R拮抗剂。在所有合成的化合物中,体外和对接研究表明,4-甲氧基-苯基取代的四氢喹唑啉胺化合物4c具有有效和选择性的H3R拮抗剂活性(IC50 <0.04μM)。化合物4c对hERG离子通道未显示任何活性,且泛测定干扰化合物的责任。药代动力学研究表明4c穿越了血脑屏障,而体内研究表明4c诱导了肥胖症的厌食症和体重减轻,但对瘦小鼠却没有。这些数据通过拮抗H3R揭示了4c作为抗肥胖候选药物的治疗潜力。